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Objectives: Medicinal products where active substance, strength, form, or 
administration route have been modified differ from generic drugs as bioequiva-
lence cannot be demonstrated. In Europe, these ‘hybrid’ products have a clear 
registration pathway (Directive 2001/83/EC) requiring investment in pre-clinical 
and clinical trials. However; beyond the regulatory pathway, pricing and market 
access remains a national matter and few countries have specific methods to 
evaluate hybrids; both innovative- and generic-like prices may result. This study 
evaluated hybrid price differences and consequences for availability of hybrids 
across Europe. MethOds: Using IMS MIDAS data and the HMA database of regis-
tered drugs, we screened 5,000 products to identify 40 hybrid products which were 
significantly differentiated from the reference product, launched between 2008-
2012 and analysed their prices and availability based on sales achieved, versus the 
reference product within and across 10 European markets. Results: Hybrid prices 
vary widely, but most frequently, generic rules are applied, limiting the interest of 
companies to make hybrids available across European markets. There is wide vari-
ation in availability of hybrids across markets, suggesting a decision not to launch 
in markets where prices are particularly unfavourable. Countries applying fixed 
generic pricing rules appear to have fewer hybrids. Yet where they are launched, 
hybrids are not classified as generics, so uptake is inhibited by non-substitution 
rules and prescribing quotas. cOnclusiOns: The lack of clear evaluation criteria 
and pricing variability within and across countries are barriers to the availability 
of hybrid products to patients in Europe. To the degree that such products bet-
ter meet patient needs versus generic medicines, these barriers reduce patient 
welfare and prescriber choice. In a context where patient-oriented outcomes are 
increasingly seen as important, hybrid drugs have a role to play given their ability 
to improve administration, compliance, convenience and in some cases improve 
safety and efficacy. Consequently, clear rules for hybrid evaluation, pricing and 
access are desirable as they would improve patient care and reduce uncertainty 
for hybrid manufacturers.
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Objectives: Coverage with evidence development (CED) in Sweden has become 
common over the last decade. It is considered as a tool to address uncertainty. The 
objective of this research is to assess from 2005 to 2012 CED in Sweden. MethOds: 
We downloaded available CED from pricing authority (TLV) database, and extracted 
detailed information in an ad hoc grid developed for that purpose. The following 
information was extracted: date of product approval, name, indication, date of CED 
installation, end of CED, type of evidence to be generated, limitation of initial file 
supporting the need of additional evidences. Results: A total of 28 cases were 
retrieved covering 9 main disease areas. Eleven were for orphan drugs and 10 for 
Central nervous system (CNS) disorders including depression anxiety, epilepsy, 
pain, ADHD, schizophrenia, restless syndrome and Parkinson disease. Other were 
classified as follow, 5 for cardiovascular disorders, 3 oncology, 2 diabetes, 2 res-
piratory disorders and 5 others. The main drivers to request CED were weak cost-
effectiveness model (14 cases) driven by uncertainty about utility, patients benefit, 
transition probabilities, model structure etc. The second reason was low relevance 
of clinical evidence for clinical practice (8 cases), followed by long term efficacy 
extrapolation (5 cases) and others mainly related to comparative effectiveness, 
daily dosage, safety, target population, etc. (11 cases). For each CED more than one 
driver could be identified. Requirements were mostly real world evidence genera-
tion. cOnclusiOns: CED in Sweden is likely to be driven more by uncertainty than 
drug prices due to low involvement of oncology, inflammation and other disease 
area where biologics are prescribed. Orphan drugs represent a leading target for CED 
as often little information is available at time of launch. Most CED are not finalised 
to assess the actual CED impact on long term coverage.
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Objectives: Studies assessing the effectiveness of new Chronic Obstructive 
Pulmonary Disease (COPD) treatments commonly use disease-specific health-
related quality-of-life (HR-QoL) instruments such as the Clinical COPD Questionnaire 
(CCQ). However, for the economic evaluations, utility data is necessary. This study 
aims to develop a model to predict mean utility values for a group of COPD patients 
using CCQ data. MethOds: We combined the data from two trials (RECODE and 
GO-AHEAD) including over 5000 observations with a broad range of disease sever-
ity. Data was randomly split into an estimation and validation sample. The overlap 
between the CCQ and EQ-5D was assessed using principal component and correla-
tion matrix analysis. Different types of models were created with increasing com-
plexity. We analysed the effect of using different observations of the same patients 
as unique observations and performed a sensitivity analysis using different EQ-5D 
value sets to estimate EQ-5D utilities. The external validity was tested with the 
dataset of the MARCH trial. Results: The principal component analyses showed 
a poor correlation of the dimension pain/discomfort with any of the CCQ items and 
the CCQ items cough and produce phlegm did not load onto any EQ-5D dimension. 
The model using ordinary least square with the individual CCQ items as dummy 
variables, controlled for sex, resulted in the best predicted performance. The mean 
procedure specified for implant registries in general. Therefore, the aim of this 
work is to identify quality criteria for the design and development of implant 
registries and to develop a minimal data set. MethOds: The systematic literature 
search was performed in different databases (Pubmed, Medline, the Cochrane 
Library, Scopus, Embase as well as the CRD York database) and different jour-
nals. Results: Ten articles were identified that describe a general implant registry 
design and structure as well as 45 articles about the creation of specific registries. 
Most recommendations for the organization of implant registries could be found 
in the field of arthroplasty. To generalize the results, it can be said, that all regis-
tries have to deliver a minimal data set including prostheses, patient and surgical 
procedure details. The geographical area, length and periodicity of data collection, 
number of patients enrolled, the composition of the team as well as information 
about security and confidentiality of data should be reported. cOnclusiOns: 
Well-structured registries are a cornerstone of the regulatory process of medical 
devices and a major tool for decison makers and managers. However, only a small 
number of papers that describe specific requirements for the construction of an 
implant registry could be identified. With the establishment of clear guidelines, the 
outcomes of the implant registries can be fundamentally improved. This project 
is supported by the German Federal Ministry of Education and Research (BMBF) as 
part of the National Cluster of Excellence‚ Medical Technologies – Medical Valley 
EMN’ (Project grant No. 13EX1013B).
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Objectives: The goal of this study is to analyse price differences triggered by 
the availability of biosimilars in developed pharmaceutical markets. MethOds: 
1) Market availability of biosimilars in the following markets was studied: Australia, 
Canada, France, Germany, Italy, Spain, UK, Japan and the United States. Biosimilars 
were selected based on their availability in these markets, and 2) Ex-factory price 
differences at launch between biosimilars and their originator counterparts were 
analysed. Results: Price differences between biosimilars and their originator 
counterpart were on average 25%. One exception aside, biosimilars always trigger 
double digit price differences. Given the limited availability of biosimilars, it is too 
soon to say if results will be consistent over time. Nevertheless, the general trend 
shows that large price differences are observed in Canada and the US (at least 
35%) and lower trends in Australia (around 16%). In the top 5 European pharma-
ceutical markets, price differences range between 17% and 30%. In Japan, price 
differences are also high, 29% on average. It should also be highlighted that the 
market entry of biosimilars does not always trigger the price of their originator 
to drop; in rare occasions only are their prices brought into line. cOnclusiOns: 
Owing to the fact that biologic drugs are commonly expensive and with double 
digit price differences between biosimilars and their originator counterpart, the 
market entry of biosimilars should enable governments to generate significant 
savings. Nevertheless, a limited number of biosimilars are at the moment approved 
and in addition to the fact that no legislation is in place in the US, there is no sign 
of improvement in the other countries studied. As a consequence, savings will 
only be achieved if governments incentivise the development of biosimilars as 
well as their use.
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Objectives: In the context of ever increasing demand and expenditure for health 
services it is important to identify policies which may maximise efficiency. Often, 
pharmaceuticals (approximately 20% of total health care expenditure) are a pri-
mary target for achieving efficiencies. This study aims to study the efficiency 
of pharmaceutical control policies. MethOds: Data on pharmaceutical policies 
and markets across 65 countries were collected from the published literature, 
with emphasis on the following domains: pricing, reimbursement, dispensing, 
expenditure and demand control. In each domain, policies were classified and 
through a multiple-country expert survey were graded for the degree of regu-
lation. Countries were clustered according to their policy mix. Principal com-
ponent analysis (PCA) served to group policies into three components: pricing 
policies, reimbursement policies and demand and cost control policies. Regression 
analysis with pharmaceutical expenditure as % of GDP as dependent variable 
was used to analyse the efficiency of policies. Independent variables were life 
expectancy, dependency ratios, mortality rates, GDP per capita and health system 
type. Results: Spearman correlation coefficients indicated that there was no 
statistically significant association between total pharmaceutical expenditure 
as % of GDP and regulation in the coverage, pricing, reimbursement, dispensing 
policy and system type. A statistically significant positive correlation between 
regulation and indirect price and cost controls (0.334, p= 0.028) and demand con-
trols (0.333, p= 0.019) implies that more regulation in these domains is associated 
with higher expenditure. Following the PCA, regulation in demand control policies 
was associated with higher expenditure (0.342, p= 0.025) and the same applies 
for the aggregate of the components (0.314, p= 0.040). In regression analysis the 
coefficients (p-value) were pricing:-0.003(0.950), demand control:0.062(p= 0.067), 
reimbursement: -0.057(0.439), mortality: 0.001(0.414), Life Expectancy: 0.062(0.474), 
elderly ratio: 0.689(0.774), GDP-per-capita: -1.788(0.017). cOnclusiOns: A variety 
of policies were developed recently to control pharmaceuticals. More regulation 
does not appear to increase efficiency or decrease expenditure.
